
UltraTech Cement shares rose 2% after Q1 profit beat estimates by 7%. Nuvama, Motilal Oswal, Jefferies, and Kotak raised price targets on volume growth and margin expansion.
Alpha Score of 68 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
UltraTech Cement shares rose 2% in Mumbai trading after the company reported first-quarter results that beat analyst estimates, prompting at least four brokerages to raise their price targets on the stock.
Nuvama lifted its target to ₹12,100 from ₹11,650, citing better-than-expected volume growth and margin expansion. The brokerage said UltraTech's cost controls offset higher fuel prices during the quarter. Motilal Oswal raised its target to ₹12,500, pointing to the company's capacity expansion plans and falling debt levels.
Jefferies and Kotak also raised their targets, with Jefferies now at ₹12,800 and Kotak at ₹12,400. Both cited the company's ability to maintain market share in a competitive pricing environment.
UltraTech reported a 12% rise in consolidated net profit to ₹1,836 crore for the quarter ended June, above the ₹1,720 crore consensus estimate. Revenue rose 8% to ₹18,528 crore. EBITDA margin came in at 22.4%, up 120 basis points from a year earlier.
The cement maker's volume grew 11% year-on-year to 33.5 million tonnes, driven by strong demand from infrastructure and housing projects. The company added 5 million tonnes of annual capacity during the quarter, taking total capacity to 156 million tonnes.
UltraTech shares have gained about 22% over the past 12 months, outperforming the Nifty 50's 18% return. The stock trades at 42 times trailing earnings, above its five-year average of 38 times.
The company plans to add another 10 million tonnes of capacity over the next 12 months, with a capital expenditure of ₹6,500 crore for the current fiscal year.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.